ABCA3 p.Pro388Arg
| Predicted by SNAP2: | A: D (53%), C: D (59%), D: D (53%), E: D (59%), F: D (75%), G: D (66%), H: D (59%), I: D (66%), K: D (59%), L: D (66%), M: D (63%), N: D (53%), Q: N (53%), R: D (63%), S: N (53%), T: N (53%), V: D (59%), W: D (85%), Y: D (66%), |
| Predicted by PROVEAN: | A: D, C: D, D: D, E: D, F: D, G: D, H: D, I: D, K: D, L: D, M: D, N: D, Q: D, R: D, S: D, T: D, V: D, W: D, Y: D, |
[switch to compact view]
Comments [show]
None has been submitted yet.
[hide] Nanomedicinal strategies to treat multidrug-resist... Nanomedicine (Lond). 2010 Jun;5(4):597-615. Dong X, Mumper RJ
Nanomedicinal strategies to treat multidrug-resistant tumors: current progress.
Nanomedicine (Lond). 2010 Jun;5(4):597-615., [PMID:20528455]
Abstract [show]
Multidrug resistance (MDR) is a major impediment to the success of cancer chemotherapy. P-glycoprotein is an important and the best-known membrane transporter involved in MDR. Several strategies have been used to address MDR, especially P-glycoprotein-mediated drug resistance in tumors. However, clinical success has been limited, largely due to issues regarding lack of efficacy and/or safety. Nanoparticles have shown the ability to target tumors based on their unique physical and biological properties. To date, nanoparticles have been investigated primarily to address P-glycoprotein and the observed improved anticancer efficacy suggests that nanomedicinal strategies provide a new opportunity to overcome MDR. This article focuses on nanotechnology-based formulations and current nanomedicine approaches to address MDR in tumors and discusses the proposed mechanisms of action.
Comments [show]
None has been submitted yet.
No. Sentence Comment
135 After immunization with these peptide-loaded liposomes and treatment with doxorubicin, an increase of 83% survival time was observed in mice inoculated with P388R cells.
X
ABCA3 p.Pro388Arg 20528455:135:157
status: NEW